Proteins are the functional macromolecules in cells, they are the main drug targets and also used as pharmaceuticals and in biotechnology. Notably, nearly 30% of proteins in eukaryotic cells are known to be membrane proteins. Mutations or improper folding of these proteins is associated with many known diseases such heart disease, cystic fibrosis, depression, obesity, cancer and many others. Currently approximately 60% of available drugs target membrane proteins.
Although most commercial drugs result from conventional discovery methods, it is the structural information provided by three-dimensional protein structures that unveils the crucial structural arrangement and atomic interactions in drug-protein complexes. This information is critical in the rational design of new drugs with improved selectivity and pharmaceutical properties.
Prometeus will address the need to provide excellent academic groups in Europe that address protein targets dealing with relevant health and technology global issues (antibiotic design, prostatic cancer, cancer theranostics, nanotechnology, food industry, agricultural pest management and aquaculture) with training in key advanced technologies provided by SME or TC large facilities.
The cutting-edge research projects will expand the breadth and the visibility of the SMEs and constitute an integrated network for future joint research grants, in the European and global context.